Skip to main content

Advertisement

SpringerLink
Log in

New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders

  • Substance Use and Related Disorders (F Levin and E Dakwar, Section Editors)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

A promising approach to addressing substance use disorders is to integrate pharmacotherapy with a behavioral treatment with which synergy is possible. In this review, we focus on recent research suggesting that this approach may be effective for cocaine and cannabis use disorders, both of which currently lack efficacious medications. We summarize potential targets of pharmacotherapy of particular relevance to combined medication-behavioral treatment and examine preliminary evidence of clinical efficacy. Common to these promising medications is a hypothesized mechanism of action predicated on reversing drug-related neural adaptations, such as high reactivity to stress or drug cues, that might undermine fruitful engagement with behavioral treatment. We also review emerging medications, such as certain glutamatergic and serotonergic agents, which may be feasibly integrated with existing treatments. We conclude with an outline of future directions for research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Shorter D, Domingo CB, Kosten TR. Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drug. 2015;20(1):15–29.

    Article  CAS  Google Scholar 

  2. Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry. 2009;21(2):96–103.

    Article  PubMed  Google Scholar 

  3. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011;17(14):1351. Also, NIDA: http://www.drugabuse.gov/publications/research-reports/marijuana/available-treatments-marijuana-use-disorders.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of Topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091–7.

    Article  CAS  PubMed  Google Scholar 

  6. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brlen CP. The effects of psychosocial services in substance abuse treatment. Addict Nurs Netw. 1993;5(2):38–47.

    Article  Google Scholar 

  7. Carroll KM, Kosten TR, Rounsaville BJ. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004;75(2):123–34.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ouimette PC, Moos RH, Finney JW. Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcomes. J Stud Alcohol. 1998;59(5):513–22.

    Article  CAS  PubMed  Google Scholar 

  9. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–60.

    Article  PubMed  Google Scholar 

  10. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70:516–27.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drugs Alcohol Abuse. 2006;32(4):503–17.

    Article  Google Scholar 

  12. Volkow ND, Li TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci. 2004;5(12):963–70.

    Article  CAS  PubMed  Google Scholar 

  13. Vanderplasschen W. Contingency management in substance abuse treatment. Addiction. 2008;103(5):857.

    Google Scholar 

  14. Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic-and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2015.

  15. Higgins ST, Silverman K, Heil SH, editors. Contingency management in substance abuse treatment. New York: Guilford Press; 2007.

    Google Scholar 

  16. Kirby KC, Benishek LA, Dugosh KL, Kerwin ME. Substance abuse treatment providers’ beliefs and objections regarding contingency management: implications for dissemination. Drug Alcohol Depend. 2006;85(1):19–27.

    Article  PubMed  Google Scholar 

  17. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2014. A good overview of the neural correlates of addictive behavior.

  18. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology. 1999;146(4):373–90.

    Article  CAS  PubMed  Google Scholar 

  19. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141(1):105–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rooke SE, Hine DW, Thorsteinsson EB. Implicit cognition and substance use: a meta-analysis. Addict Behav. 2008;33(10):1314–28.

    Article  PubMed  Google Scholar 

  21. Bickel WK, Marsch LA. Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction. 2001;96(1):73–86.

    Article  CAS  PubMed  Google Scholar 

  22. Bates ME, Bowden SC, Barry D. Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol. 2002;10(3):193.

    Article  CAS  PubMed  Google Scholar 

  23. Bowden SC, Crews FT, Bates ME, Fals‐Stewart W, Ambrose ML. Neurotoxicity and neurocognitive impairments with alcohol and drug-use disorders: potential roles in addiction and recovery. Alcohol Clin Exp Res. 2001;25(2):317–21.

    Article  CAS  PubMed  Google Scholar 

  24. Jurado MB, Rosselli M. The elusive nature of executive functions: a review of our current understanding. Neuropsychol Rev. 2007;17(3):213–33.

    Article  PubMed  Google Scholar 

  25. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol. 2008;154(2):327–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75(1):218–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 1998;12(1):54–67.

    Article  PubMed  Google Scholar 

  28. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatr. 2002;159(10):1642–52.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012;100(4):801–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized control trials. Addiction. 2016.

  31. Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry. 2012, 3.

  32. Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1–22.

    Article  CAS  PubMed  Google Scholar 

  33. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–98.

    Article  CAS  PubMed  Google Scholar 

  34. Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: response to treatment linked to neurochemistry. Am J Psychiatry. 2011;168(6):634–41. doi:10.1176/appi.ajp.2010.10050748.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev. 2014;66(1):193–221.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009;101(1–2):34–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Schmitz JM, Mooney ME, Gerard Moeller F, Stotts AL, Charles G, John G. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008;94(1–3):142–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol. 2010;18(3):238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70(3):315–25.

    Article  CAS  PubMed  Google Scholar 

  40. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63(2):219–28.

    Article  CAS  PubMed  Google Scholar 

  41. Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse. 2007;33(3):367–78.

    Article  PubMed  Google Scholar 

  42. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68–77. doi:10.1016/j.tins.2011.11.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Markou A, Koob GF. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology. 1991;4(1):17–26.

    CAS  PubMed  Google Scholar 

  44. Kalivas PW, LaLumiere R, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology. 2009;56 suppl 1:169–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend. 2010;111(1–2):97–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry. 2012;72(11):950–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol. 2010;21(5–6):514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci. 2009;12:182–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169(8):805–12. This manuscript suggests that NAC might facilitate CM-based approaches for cannabis dependence by normalizing NAcc functioning.

    Article  PubMed  PubMed Central  Google Scholar 

  50. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm R. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013;22(5):443–52.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Kadden R. Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence (No. 94). DIANE Publishing;1995.

  52. Marlatt GA, Donovan DM, editors. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press; 2005.

    Google Scholar 

  53. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT. Understanding and preventing relapse. Am Psychol. 1986;41(7):765.

    Article  CAS  PubMed  Google Scholar 

  54. Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ., et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry.2015. This manuscript demonstrates the importance of addressing comorbid vulnerabilities, such as ADHD, to facilitate effective treatment for cocaine use disorders.

  55. Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am. 1998;21(4):761–74.

    Article  CAS  PubMed  Google Scholar 

  56. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology. 2006;31(5):1036–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Skolnick P, Popik P, Trullas P. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563–9.

    Article  CAS  PubMed  Google Scholar 

  58. Zarate Jr C, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293–303.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Monteggia LM, Zarate Jr C. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol. 2015;30C:139–43.

    Article  Google Scholar 

  60. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergicneurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921–7.

    CAS  PubMed  Google Scholar 

  61. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors. Biol Psychiatry. 2008;63:349–52.

    Article  CAS  PubMed  Google Scholar 

  62. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;20:959–64.

    Article  Google Scholar 

  63. Liu RJ, Lee FS, Li XY, et al. BDNF Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2010;71:996–1005.

    Article  Google Scholar 

  64. Belujon P, Jakobowski NL, Dollish HK, Grace AA. Withdrawal from acute amphetamine induces an amygdala-driven attenuation of dopamine neuron activity: reversal by ketamine. Neuropsychopharmacology. 2015.

  65. Berglind WJ, See RE, Fuchs RA, et al. A BDNF infusion into the medial prefrontal cortex suppresses cocaine seeking in rats. Eur J Neurosci. 2007;26(3):757–66.

    Article  PubMed  Google Scholar 

  66. Scheidegger M, Walter M, Lehmann M, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7(9):e4479.

    Article  Google Scholar 

  67. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65(4):289–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, Schmahl C, et al. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry. 2010;67(9):946–54.

    Article  CAS  PubMed  Google Scholar 

  69. Kosten TA, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, et al. Cue-induced brain activity changes and relapse in cocaine dependent patients. Neuropsychopharmacology. 2006;31:644–50.

    Article  CAS  PubMed  Google Scholar 

  70. Matuskey D, Luo X, Zhang S, et al. Methylphenidate remediates error-preceding activation of the default mode brain regions in cocaine-addicted individuals. Psychiatry Res. 2013;214(2):116–21.

    Article  CAS  PubMed  Google Scholar 

  71. Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P. Differences in degree of trapping of low-affinity noncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. Pharmacol Exp Ther. 1999;288(1):204–10.

    CAS  Google Scholar 

  72. Dakwar E, Levin FR, Foltin R, Nunes EV, Hart CL. The effect of sub-anesthetic ketamine on motivation to quit and cue-induced craving in cocaine dependent research volunteers. Biol Psychiatry. 2014.

  73. Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, cross-over trial. Mol Psychiatry. 2016. doi:10.1038/mp.2016.39.

  74. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165–83.

    Article  CAS  PubMed  Google Scholar 

  75. Krupitsky EM, Grineko AY, Berkaliev TN, Paley AI, Tetrov UN, Mushkov KA, et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcohol Treat Q. 1992;9(1):99–105.

    Article  Google Scholar 

  76. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutametergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist. 2009;15(5):525–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Preskhorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagnosist, CP-101.606, in patients with treatment refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–7.

    Article  Google Scholar 

  78. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40(2):259–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015;225(1–2):1–13.

    Article  CAS  PubMed  Google Scholar 

  80. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268–83.

    Article  CAS  PubMed  Google Scholar 

  81. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014, 0269881114548296.

  82. Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. James W. The varieties of religious experience: a study in human nature. Oxford: Oxford World’s Classics; 1907.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division on Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons at Columbia University Medical Center, New York, NY, USA

    Elias Dakwar & Edward V. Nunes

Authors
  1. Elias Dakwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward V. Nunes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elias Dakwar.

Ethics declarations

Conflict of Interest

Elias Dakwar and Edward V. Nunes declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Substance Use and Related Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dakwar, E., Nunes, E.V. New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. Curr Psychiatry Rep 18, 64 (2016). https://doi.org/10.1007/s11920-016-0703-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-016-0703-4

Keywords

Search

Navigation